Cingulate Inc. Other Income and Expense
Cingulate Inc. (CING) reported Other Income and Expense of -$573.06 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2025-11-13
- Cingulate Inc. nonoperating income (expense) for the quarter ending 2025-09-30 was -$573.06K, a 1235.15% decline year-over-year.
- Cingulate Inc. nonoperating income (expense) for the quarter ending 2025-06-30 was -$138.76K.
- Cingulate Inc. nonoperating income (expense) for the quarter ending 2025-03-31 was -$96.66K.
- Cingulate Inc. nonoperating income (expense) for the quarter ending 2024-12-31 was $76.51K.
- Cingulate Inc. nonoperating income (expense) for fiscal 2024 was $99.24K.
- Cingulate Inc. nonoperating income (expense) for fiscal 2023 was -$775.76K.
- Cingulate Inc. nonoperating income (expense) for fiscal 2022 was -$174.51K.
- Cingulate Inc. nonoperating income (expense) for fiscal 2021 was -$30.59K.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$573.06K 10-Q · filed 2025-11-13 | -$711.82K derived: sum of 2 quarters · filed 2025-11-13 | -$808.48K 10-Q · filed 2025-11-13 | -$731.97K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | -$138.76K 10-Q · filed 2025-08-19 | -$235.42K 10-Q · filed 2025-08-19 | -$158.91K derived: sum of 3 quarters · filed 2025-08-19 | -$108.42K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-03-31 | -$96.66K 10-Q · filed 2025-05-08 | -$20.15K derived: sum of 2 quarters · filed 2025-05-08 | $30.34K derived: sum of 3 quarters · filed 2025-11-13 | $26.84K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | $76.51K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $126.99K derived: sum of 2 quarters · filed 2025-11-13 | $123.50K derived: sum of 3 quarters · filed 2025-11-13 | $99.24K 10-K · filed 2025-03-27 |
| 2024-09-30 | $50.48K 10-Q · filed 2025-11-13 | $46.99K derived: sum of 2 quarters · filed 2025-11-13 | $22.73K 10-Q · filed 2025-11-13 | -$114.82K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$3.50K 10-Q · filed 2025-08-19 | -$27.76K 10-Q · filed 2025-08-19 | -$165.30K derived: sum of 3 quarters · filed 2025-08-19 | -$394.68K derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | -$24.26K 10-Q · filed 2025-05-08 | -$161.81K derived: sum of 2 quarters · filed 2025-05-08 | -$391.19K derived: sum of 3 quarters · filed 2025-05-08 | -$645.13K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$137.55K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$366.93K derived: sum of 2 quarters · filed 2025-03-27 | -$620.87K derived: sum of 3 quarters · filed 2025-03-27 | -$775.76K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$229.38K 10-Q · filed 2024-11-07 | -$483.32K derived: sum of 2 quarters · filed 2024-11-07 | -$638.21K 10-Q · filed 2024-11-07 | -$768.21K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$253.94K 10-Q · filed 2024-08-13 | -$408.83K 10-Q · filed 2024-08-13 | -$538.83K derived: sum of 3 quarters · filed 2024-08-13 | -$597.72K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$154.89K 10-Q · filed 2024-05-08 | -$284.89K derived: sum of 2 quarters · filed 2024-05-08 | -$343.78K derived: sum of 3 quarters · filed 2024-05-08 | -$335.41K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$188.89K derived: sum of 2 quarters · filed 2024-04-01 | -$180.52K derived: sum of 3 quarters · filed 2024-04-01 | -$174.51K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$58.88K 10-Q · filed 2023-11-13 | -$50.52K derived: sum of 2 quarters · filed 2023-11-13 | -$44.51K 10-Q · filed 2023-11-13 | -$51.28K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $8.37K 10-Q · filed 2023-08-14 | $14.20K 10-Q · filed 2023-08-14 | $7.60K derived: sum of 3 quarters · filed 2023-08-14 | -$2.96K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $5.83K 10-Q · filed 2023-05-10 | -$766.00 derived: sum of 2 quarters · filed 2023-05-10 | -$11.32K derived: sum of 3 quarters · filed 2023-05-10 | -$21.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$6.60K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$17.16K derived: sum of 2 quarters · filed 2023-03-10 | -$26.83K derived: sum of 3 quarters · filed 2023-03-10 | -$30.59K 10-K · filed 2023-03-10 |
| 2021-09-30 | -$10.56K 10-Q · filed 2022-11-14 | -$20.23K derived: sum of 2 quarters · filed 2022-11-14 | -$23.99K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$9.68K 10-Q · filed 2022-08-11 | -$13.44K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$3.76K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$100.25K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |